🟢 Mirum Pharmaceuticals is trading 4.15% up in pre-market ahead of Oct. 12, 2026 results call

Mirum Pharmaceuticals is trading at $89.58, up 4.15%, ahead of an investor call on topline Phase 3 EXPAND results.

• The call is scheduled for October 12, 2026, and will cover LIVMARLI in ultra-rare cholestatic liver diseases; results were not disclosed.
• Shares rose 5.73% on October 9 after previously reported positive AZURE-1 data and an RBC price-target increase.
• No separate pre-market trading-volume figure was available.